Two big pharma execs share the same challenges, but compensation? They’re not even close

Big Pharma execs may share big concerns like the battle over drug pricing, big patent cliffs and the dilemma over pipeline productivity, but they don’t get paid the same.

A brief glimpse of 2 new SEC filings from AbbVie $ABBV and Sanofi $SNY underscore the chasm of wealth that can separate peers in this lofty realm.